Title: Reinduction of trastuzumab after symptomatic heart failure in a patient with metastatic breast cancer
Abstract: Introduction: Trastuzumab is a monoclonal antibody directed against the HER2/neu protein. It is effectively used as a therapeutic agent in the adjuvant and metastatic setting of breast cancer overexpressing the HER2/neu marker. Trastuzumab was demonstrated to be synergistic with different cytotoxic agents. A known adverse effect of trastuzumab therapy is heart failure due to cardiomyopathy.
Publication Year: 2006
Publication Date: 2006-09-19
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot